These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 19109014)

  • 41. [Contributions to the physical chemistry and pharmacology of emulsified tar derivatives with special consideration of the surface activated Encarbol].
    SEIDMANN H
    Schweiz Arch Tierheilkd; 1948 Apr; 90(4):198-202. PubMed ID: 18873087
    [No Abstract]   [Full Text] [Related]  

  • 42. Small Molecules Targeting Viral RNA.
    Mathez G; Cagno V
    Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37686306
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Non-Natural Linker Configuration in 2,6-Dipeptidyl-Anthraquinones Enhances the Inhibition of TAR RNA Binding/Annealing Activities by HIV-1 NC and Tat Proteins.
    Sosic A; Saccone I; Carraro C; Kenderdine T; Gamba E; Caliendo G; Corvino A; Di Vaio P; Fiorino F; Magli E; Perissutti E; Santagada V; Severino B; Spada V; Fabris D; Frecentese F; Gatto B
    Bioconjug Chem; 2018 Jul; 29(7):2195-2207. PubMed ID: 29791798
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Iron(II) supramolecular helicates interfere with the HIV-1 Tat-TAR RNA interaction critical for viral replication.
    Malina J; Hannon MJ; Brabec V
    Sci Rep; 2016 Jul; 6():29674. PubMed ID: 27405089
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Structure-activity studies of RNA-binding oxazolidinone derivatives.
    Maciagiewicz I; Zhou S; Bergmeier SC; Hines JV
    Bioorg Med Chem Lett; 2011 Aug; 21(15):4524-7. PubMed ID: 21733684
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Multivalent binding oligomers inhibit HIV Tat-TAR interaction critical for viral replication.
    Wang D; Iera J; Baker H; Hogan P; Ptak R; Yang L; Hartman T; Buckheit RW; Desjardins A; Yang A; Legault P; Yedavalli V; Jeang KT; Appella DH
    Bioorg Med Chem Lett; 2009 Dec; 19(24):6893-7. PubMed ID: 19896372
    [TBL] [Abstract][Full Text] [Related]  

  • 47. 2-Phenylquinolones as inhibitors of the HIV-1 Tat-TAR interaction.
    Gatto B; Tabarrini O; Massari S; Giaretta G; Sabatini S; Del Vecchio C; Parolin C; Fravolini A; Palumbo M; Cecchetti V
    ChemMedChem; 2009 Jun; 4(6):935-8. PubMed ID: 19283692
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Design, synthesis, and biological evaluation of novel quinoline derivatives as HIV-1 Tat-TAR interaction inhibitors.
    Chen S; Chen R; He M; Pang R; Tan Z; Yang M
    Bioorg Med Chem; 2009 Mar; 17(5):1948-56. PubMed ID: 19217787
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A new class of HIV-1 Tat antagonist acting through Tat-TAR inhibition.
    Hamy F; Brondani V; Flörsheimer A; Stark W; Blommers MJ; Klimkait T
    Biochemistry; 1998 Apr; 37(15):5086-95. PubMed ID: 9548739
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Orientation and affinity of HIV-1 Tat fragments in Tat-TAR complex determined by fluorescence resonance energy transfer.
    Cao H; Tamilarasu N; Rana TM
    Bioconjug Chem; 2006; 17(2):352-8. PubMed ID: 16536465
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Tackling Tat.
    Karn J
    J Mol Biol; 1999 Oct; 293(2):235-54. PubMed ID: 10550206
    [TBL] [Abstract][Full Text] [Related]  

  • 52. HIV-1 TAT and IMMUNE DYSREGULATION in AIDS PATHOGENESIS: a THERAPEUTIC TARGET.
    Chiozzini C; Toschi E
    Curr Drug Targets; 2016; 17(1):33-45. PubMed ID: 26302810
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Synthesis and biological evaluation of 2-phenylquinolones targeted at Tat/TAR recognition.
    Manfroni G; Gatto B; Tabarrini O; Sabatini S; Cecchetti V; Giaretta G; Parolin C; Del Vecchio C; Calistri A; Palumbo M; Fravolini A
    Bioorg Med Chem Lett; 2009 Feb; 19(3):714-7. PubMed ID: 19109014
    [TBL] [Abstract][Full Text] [Related]  

  • 54.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 55.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 56.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 57.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 58.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]     [New Search]
    of 3.